Lipid Emulsion (ILE) protocol

20% intravenous lipid emulsion as an antidote for lipophilic toxicoses. The lipid-sink mechanism sequesters fat-soluble toxins (local anesthetics, calcium-channel and beta-blocker overdoses, permethrin, ivermectin in MDR1-deficient breeds, baclofen) into a lipophilic plasma compartment. Two practice protocols (fast and slow) shown side-by-side; selection depends on indication acuity, cardiovascular stability, and patient size. Cumulative dose tracked against a conservative guideline, not a hard ceiling.

Open calculator →

Clinical background

Intravenous lipid emulsion (ILE) is a 20% lipid suspension administered as an antidote for lipophilic toxicoses. The original indication is local anesthetic systemic toxicity (LAST), described in the human regional-anesthesia literature in the early 2000s after a series of cardiac arrests from bupivacaine overdose were reversed by lipid emulsion administration. The clinical adoption in veterinary medicine followed during the 2010s, expanding the indication set to include calcium-channel and beta-blocker overdoses, permethrin toxicity in cats, ivermectin and other macrocyclic lactone toxicity (particularly in MDR1-deficient breeds), baclofen toxicity, and a growing list of lipophilic toxicants. The clinical pivot is the “lipid sink” mechanism: the 20% emulsion creates a lipophilic plasma compartment that sequesters fat-soluble toxins away from their sites of action.

Pharmacology

The 20% emulsion (200 mg/mL of fat, principally soybean-oil-derived triglycerides) creates a lipophilic plasma phase that partitions lipophilic toxins out of aqueous plasma and tissue:

• Lipid sink (sequestration): the dominant mechanism, particularly for highly lipid-soluble drugs (log P > 2). The toxin redistributes from tissue and from aqueous plasma into the emulsion, reducing the effective concentration at receptors and channels.
• Direct cardiovascular effect: free fatty acids generated by the emulsion provide an alternative energy substrate for cardiac myocytes, which may explain the speed of cardiovascular response in LAST and CCB toxicity even before the redistribution effect is complete.
• Possible direct ion-channel effect: high-dose fatty acids have been shown to modulate cardiac sodium and calcium channels in vitro; the clinical relevance of this contribution is unclear.
• Possible competitive binding at receptor sites for very-lipid-soluble drugs, though this is contested in the mechanism literature.

Onset is rapid. Cardiovascular improvement after bolus delivery is typically seen within 2–5 minutes in responsive patients. The duration of effect tracks the duration of the infusion and the kinetics of toxin redistribution; intermittent re-bolus dosing or sustained CRI is the standard approach rather than a single bolus.

The emulsion is metabolized through normal triglyceride pathways: lipoprotein lipase hydrolysis at the capillary endothelium, free fatty acid uptake by tissues, and storage or oxidation. Clearance from plasma is rapid in healthy animals (half-life under an hour) but accumulates with repeated dosing.

Indications

Primary use cases:

• Local anesthetic systemic toxicity (LAST), particularly bupivacaine and ropivacaine overdose. The original indication. Inadvertent intravascular injection during regional or local anesthesia, accidental overdose during continuous infusion. ILE is the first-line antidote when LAST progresses to cardiovascular compromise or seizures.
• Calcium channel blocker overdose, particularly diltiazem and amlodipine. CCB toxicity produces refractory bradycardia, AV block, hypotension, and cardiogenic shock that may not respond adequately to calcium, glucagon, or pressors. ILE improves cardiovascular function in this setting, often dramatically.
• Beta-blocker overdose, particularly propranolol and atenolol. Similar pattern to CCB toxicity; ILE is part of the response package alongside glucagon and pressors.
• Permethrin toxicity in cats (topical exposure to dog flea-and-tick products). The lipophilic pyrethroid responds to ILE adjunct therapy, alongside methocarbamol for tremor control and standard decontamination.
• Ivermectin and other macrocyclic lactone toxicity, particularly in MDR1-deficient breeds (Collies, Australian Shepherds, Long-haired Whippets, Old English Sheepdogs) where the blood-brain barrier deficit allows entry of ivermectin into the CNS at standard heartworm-prevention doses. ILE reduces CNS lipid-phase concentration of the drug.
• Baclofen toxicity, particularly accidental ingestion in dogs. The clinical picture is depression, ataxia, hypothermia, and respiratory depression. ILE reduces plasma and tissue baclofen concentrations.
• Tricyclic antidepressant toxicity (amitriptyline, clomipramine) when significant cardiac or CNS involvement is present.
• Other lipophilic toxicants with reported case-series support: cholecalciferol, marijuana (THC), some opioid overdoses, lamotrigine, propofol overdose, certain insecticides.

ILE is most effective for highly lipophilic drugs. For water-soluble toxins (most aminoglycosides, most water-soluble cardiac glycosides) the lipid-sink mechanism is irrelevant and ILE adds no benefit. The lipophilicity threshold roughly corresponds to log P > 1.0; above log P 2.0 the response tends to be strong.

ILE is supportive, not definitive. It works alongside the other components of toxicology care: decontamination (where indicated), specific antidotes (where they exist), and standard supportive care (fluids, pressors, antiarrhythmics, ventilation, body-temperature management). It is not a substitute for those measures.

The protocols

Two regimens are in established veterinary practice. The calculator shows both side-by-side rather than choosing for the clinician, because protocol selection depends on indication acuity, cardiovascular stability, and patient size, not weight alone.

Fast (ASRA-derived). 1.5 mL/kg bolus over 2–3 minutes, followed by 0.25 mL/kg/min CRI for 30 minutes (standard) or 60 minutes (extended, refractory). The original LAST rescue protocol; preferred for acute cardiovascular collapse, larger patients, and rapid reversal indications. For a 20 kg dog: bolus 30 mL, CRI 5 mL/min (300 mL/hr), 30-min total 180 mL.

Slow (conservative). Same 1.5 mL/kg bolus, followed by 0.066 mL/kg/min CRI for 240 minutes. Used in smaller patients (the Munich retrospective documented this for dogs in the ~15 kg range and below), in cardiovascular instability where the fast protocol’s volumetric load is poorly tolerated, and in sustained toxicities (permethrin, ivermectin, baclofen) where ongoing lipid sink coverage outlasts a 30–60 min infusion. For a 20 kg dog: same bolus, CRI 1.32 mL/min (79.2 mL/hr), 4-hr total 347 mL.

Re-bolus. 1.5 mL/kg may be repeated if cardiovascular response remains inadequate at any point during or after the initial protocol. Each rebolus adds 1.5 mL/kg to the cumulative dose.

Cumulative dose handling

No validated maximum daily dose exists in veterinary patients. The 10 mL/kg/day figure cited in older protocols is conservative-practice extrapolation from human ASRA’s 12 mL/kg recommendation, not a hard ceiling. VETgirl cites 8 mL/kg/day “although that is debated.”

Mechanistically, fat overload syndrome is rate-driven: peak plasma triglyceride exceeding the rate of hydrolysis, free fatty acid uptake, and clearance. This is why the slow protocol can deliver similar or higher cumulative volumes than the fast protocol at materially lower fat-overload risk. The slow protocol’s peak triglyceride load is approximately 25% of the fast protocol’s at the same per-kg total.

The calculator classifies each protocol’s cumulative dose (bolus + CRI, expressed per-kg) into three tiers:

• Within conservative guideline (≤ 10 mL/kg): Fernandez 2011 recommendation; comfortable.
• Above conservative guideline (10–15 mL/kg): routinely seen in practice, particularly for the slow protocol and for any protocol after one rescue rebolus.
• High cumulative (> 15 mL/kg): approaches the human ASRA upper bound. Check serum lipemia, fat-overload markers (triglycerides, hemolysis, transaminases), and clinical status before continuing.

Stopping criteria are clinical, not numeric: clinical response, lipemia status before any repeat dose, and fat-overload signs. The tier flags are checkpoints, not stop signs.

For a 20 kg dog, the math: fast 30-min protocol delivers 9 mL/kg total (within); fast 60-min delivers 16.5 mL/kg (high); slow 4-hr delivers 17.34 mL/kg (high). For smaller patients the math is the same on a per-kg basis, which is why the tier classification is patient-size-independent for these standardized protocols.

Administration

20% lipid emulsion ONLY. The 10% formulation delivers half the effective dose per mL with double the fluid load and is not appropriate for toxicology reversal. Read the bag: Intralipid 20%, SMOFlipid 20%, Liposyn 20%, or veterinary-equivalent.

Use a dedicated IV line where possible. Lipid emulsion is incompatible with calcium-containing solutions and sodium bicarbonate (precipitation). If a Y-site is unavoidable, flush thoroughly before and after lipid administration.

The infusion can be given through a syringe pump or a standard IV infusion pump; for the high rates required during the CRI (300 mL/hr in a 20 kg dog), an infusion pump is more practical than a syringe pump.

Stability: an opened bag is stable at room temperature for 24 hours. Discard any unused portion after that window for sterility reasons. Refrigeration is not required for the brief duration of toxicology use.

Concurrent propofol

Propofol vehicle is the same 10% lipid emulsion at the formulation level (although propofol is 1% drug in lipid emulsion). The clinical implications:

• Patients sedated with propofol at the time of ILE administration have an additional lipid load that should be counted toward the cumulative daily dose. Most propofol-sedated patients have not received enough propofol to push the total over the daily cap, but it matters in long-running propofol sedations.
• Triglyceride monitoring in the post-ILE period is confounded by recent propofol infusion. The lipemia from either source looks the same on the lipid panel.
• Switching sedation off propofol to an alternative (alfaxalone, dexmedetomidine, midazolam) is reasonable in patients who are about to receive sustained ILE therapy.

Lab interference

Lipemia from ILE administration interferes with most subsequent biochemistry assays for hours after the infusion. Affected analytes commonly include:

• Glucose, electrolytes, total protein and albumin (interference with photometric methods)
• Liver enzymes (lipid interference at the same wavelengths)
• Bilirubin, lactate (variable interference)
• Coagulation testing (variable, generally less affected than chemistry)
• Cardiac troponin and BNP (assay-dependent; some methods are more lipid-tolerant)

The practical implication is to draw all essential baseline labs BEFORE starting ILE. CBC, chemistry panel, blood gas, lactate, cardiac biomarkers if indicated, and any toxin-specific labs are easier to interpret pre-infusion. Post-infusion lab interpretation requires either delaying the labs (often impractical in an unstable patient) or accepting the limitations of lipid-affected results.

Drug interactions

• Propofol: lipid load additive (see above).
• Drugs administered through the same line: incompatible with calcium-containing solutions (precipitation), sodium bicarbonate (precipitation), and some lipophilic drugs that partition into the emulsion phase and lose effect (this is the mechanism of action for ILE-treated toxins; for therapeutically administered drugs, this is an unwanted effect).
• Vasopressors: the cardiovascular response to ILE can produce sudden hypotension correction that combines with concurrent vasopressor administration; reassess pressor doses 5–10 minutes after ILE bolus to avoid hypertension.
• Anticoagulants: the emulsion itself has not been shown to affect coagulation, but the lab-interference issue (see above) can complicate INR or PT monitoring in patients on warfarin.

Adverse effects

• Fat overload syndrome at high cumulative doses or in pancreatitis-prone patients: hyperlipidemia, hepatosplenomegaly, coagulopathy, hemolysis. The 10 mL/kg/day cap is set conservatively to mitigate this; severe cases require supportive care and discontinuation.
• Pancreatitis in predisposed breeds, particularly Miniature Schnauzers and other lipid-metabolism-sensitive breeds. The risk is dose-related; brief therapy is generally well tolerated, sustained or repeated dosing raises the risk.
• Allergic reactions to soybean oil, egg phospholipid, or other emulsion components. Rare but reported. Patients with documented soy or egg allergy should receive ILE only when the benefit clearly outweighs the risk, and pretreatment with antihistamines may be considered.
• Hyperlipidemia of clinical significance in patients with underlying lipid metabolism disorders.
• Local irritation at the infusion site, infrequent at the working concentration.
• Transient interference with pulse oximetry through lipemia at the sensor; readings can be unreliable for several hours.

Monitoring

• Continuous ECG and blood pressure during and for at least 30 minutes after the infusion. The cardiovascular response in successful reversal can be dramatic and rapid.
• Repeat physical examination every 5–10 minutes during the active protocol. Mental status, respiratory pattern, mucous membrane color, and pulse quality are the bedside flags for response or non-response.
• Body temperature in toxicities that drive hyperthermia (pyrethroid in cats, severe tremoring with any cause).
• CBC, chemistry, and triglycerides 4–6 hours after the protocol. Assess for fat overload markers (hyperlipidemia, hemolysis, transaminase elevation) and confirm electrolyte and acid-base status now that lab interference has subsided.
• Coagulation testing at 12–24 hours after large total doses (>1.5 boluses plus 60-min CRI).
• Urine output as a perfusion marker and for evidence of pigmenturia if hemolysis develops.
• Pulse oximetry with awareness of the lipemia interference issue; arterial blood gas is more reliable in the immediate post-infusion period.

Post-infusion care

The CRI is the bridge across the toxic interval, not the cure. Ongoing supportive care is what carries the patient through to recovery:

• Continue vasopressors, antiarrhythmics, and respiratory support as indicated by the underlying toxicity
• Continue toxin-specific antidotes where they exist (atropine for organophosphate, naloxone for opioid, glucagon for beta-blocker)
• Continue decontamination (activated charcoal where time and clinical status permit, repeat bathing for topical exposures)
• Recheck triglycerides at 4–6 hours and at 12–24 hours after the protocol; clearing lipemia is expected within 12 hours in animals with normal lipid metabolism
• Document the cumulative ILE dose, the indication, the response, and the post-infusion lab trajectory. The case-series literature in veterinary toxicology depends on this documentation to inform future practice

Sources

• Plumb’s Veterinary Drugs, intravenous lipid emulsion monograph (current edition).
• Fernandez AL, Lee JA, Rahilly L, Hovda L, Brutlag AG, Engebretsen K. The use of intravenous lipid emulsion as an antidote in veterinary toxicology. J Vet Emerg Crit Care. 2011;21(4):309–320. (The foundational veterinary review establishing the fast protocol and the conservative 10 mL/kg/day guideline.)
• Gwaltney-Brant SM, Meadows I. Intravenous lipid emulsions in veterinary clinical toxicology. Vet Clin North Am Small Anim Pract. 2018;48(6):933–942. (Documents the 0.06–0.5 mL/kg/min infusion range and the slow-protocol approach for smaller patients and sustained toxicities. Cites the absence of a validated maximum daily dose in veterinary patients.)
• Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017. Reg Anesth Pain Med. 2018;43(2):113–123. (The human ASRA protocol from which the vet fast protocol is derived.)
• Hayes WK, Brown SR, Hodgson HA, et al. Intravenous lipid emulsion therapy for permethrin toxicosis in cats. J Vet Emerg Crit Care. 2020;30(5):608–614. (Specific feline evidence for the permethrin indication.)
• Bates N, Chatterton J, Robbins C, et al. Lipid infusion in the management of poisoning: a report of 6 canine cases. Vet Rec. 2013;172(13):339. (Early UK case series across several toxicities.)
• ASPCA Animal Poison Control Center protocols for lipophilic toxicoses.